Recent Reports

ICER’s Evidence Report on disease-modifying therapies for multiple sclerosis. This report will the subject of a February 2017 meeting of the California Technology Assessment Forum.

View More on this Topic

A draft evidence report on treatments for rheumatoid arthritis. This report will be open to public comment until February 17, 2017. Find more information on how to submit a public comment here.

View More on this Topic

ICER’s final report reviewing the comparative clinical effectiveness and value of targeted immunomodulators for treatment of moderate to severe plaque psoriasis. The report includes a summary of voting and policy implications from a November 2016 meeting of the New England CEPAC in Boston, MA.

View More on this Topic

ICER’s final evidence report on TKIs and PD-1 immunotherapies for treatment of advanced non-small cell lung cancer. The report also includes a summary of votes taken during a public meeting of the Midwest CEPAC, along with and key policy implications stemming from the meeting.

View More on this Topic

Materials

Midwest CEPAC

Atopic Dermatitis: Model Analysis Plan

Midwest CEPAC

Atopic Dermatitis: Research Protocol

CTAF

Multiple Sclerosis: Evidence Presentation

CTAF

Multiple Sclerosis: ICER’s Response to Public Comments

CTAF

Multiple Sclerosis: Revised Voting Questions

New England CEPAC

Abuse-Deterrent Opioids: Model Analysis Plan

New England CEPAC

Rheumatoid Arthritis: Draft Voting Questions

New England CEPAC

Rheumatoid Arthritis: Stakeholder List

CTAF

Behavioral Health Integration: California Action Guide (Spanish)

CTAF

Obesity Management: Action Guide (Spanish)

CTAF

Diabetes Mellitus: Report-at-a-Glance (Spanish)

CTAF

Asthma: Report-at-a-Glance (Spanish)